| | | |
| Mesothelioma |
NCT06097728
D7988C00001, 2023-503231-17-00,2023-000067-32 | A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso) | Dr. Penelope Bradbury | Mesothelioma |
| Multiple Sites |
NCT05067283
1084-001, MK-1084-001,jRCT2041220034,2022-501563-40,U1111-1281-2482 | A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors | Dr. Adrian Sacher | Multiple Sites |
NCT05094336
20210023, 2023-504363-17 | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors | Dr. Adrian Sacher | Multiple Sites |
NCT05789082
BO44426, 2022-003048-28,2023-507171-22-00 | A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Dr. Adrian Sacher | Multiple Sites |
| Non Small Cell Lung Cancer (NSCLC) |
NCT04093167
BR36, CRI-CCTG-002 | A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT05975073
20220127 | A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT04956640
LOXO-RAS-20001, 2021-000595-12,J3M-OX-JZQA,MK-3475-E27/KEYNOTE E27,2022-502756-31-00 | A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT05118789
NVL-520-01 | A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1) | Dr. Geoffrey Liu | Non Small Cell Lung Cancer (NSCLC) |
NCT04614103
IOV-LUN-202, 2020-003629-45,2024-510778-26-00 | A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT06452277
22615, 2024-511319-91-00 | A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT05668988
DZ2022E0005 | A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation | Dr. Geoffrey Liu | Non Small Cell Lung Cancer (NSCLC) |
NCT04449874
GO42144, 2020-000084-22,2023-506311-18-00 | A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Dr. Adrian Sacher | Non Small Cell Lung Cancer (NSCLC) |
NCT05221840
D9078C00001, 2023-503999-24-00,2021-004346-37 | A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy | Dr. Frances Shepherd | Non Small Cell Lung Cancer (NSCLC) |
NCT05261399
D5087C00001, 2024-511169-12-00,2021-006374-24 | A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON). | Dr. Frances Shepherd | Non Small Cell Lung Cancer (NSCLC) |
NCT06074588
2870-004, 2023-503539-16,jRCT2031240108,U1111-1287-4913 | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT06305754
2870-009, 2023-504910-31,U1111-1288-3804,MK-2870-009,jRCT2071240041 | A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT05048797
D967SC00001, 2023-503674-20-00,2021-000634-33 | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) | Dr. Penelope Bradbury | Non Small Cell Lung Cancer (NSCLC) |
NCT04966663
ctDNA Lung RCT | From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
NCT04335292
OCELOT | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge | Dr. Geoffrey Liu | Non Small Cell Lung Cancer (NSCLC) |
NCT03991819
18-5856, BiniPembro | Phase I/Ib Study of Binimetinib, a MEK Inhibitor, in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. Natasha Leighl | Non Small Cell Lung Cancer (NSCLC) |
